ICON plc November 2009
description
Transcript of ICON plc November 2009
ICON plcNovember 2009
Forward Looking Statements
Certain statements contained herein including, without limitation, statements containing the words “believes,” “anticipates,” “intends,” “expects” and words of similar import, constitute forward-looking statements concerning the Company's operations, performance, financial condition and prospects. Because such statements involve known and unknown risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors are cautioned not to place undue reliance on such forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
This presentation includes selected non-GAAP financial measures. For a presentation of the most directly comparable GAAP financial measures, please refer to the Quarter 3 2009 press release consolidated income statement headed Consolidated Income Statements (Unaudited) (US GAAP)
Global Full Service Clinical Development
ICONs Global Footprint
ICON Plc Staff Growth 1990 - Today
Market Environment
Market Fundamentals Still Intact
• Outsourcing Penetration expected to increase– More Strategic approach to outsourcing– Cost containment– Globalisation of clinical research
• Continued R&D Spending Growth.– Pipelines remain solid– Scientific innovation continues to expand
• Increasing Regulation – More patients/ more studies– Post marketing surveillance
Increased Outsourcing
• Clients are increasingly focused on their core competencies of– Discovery– Strategic Development– Marketing
• Clients are engaging CROs at a more strategic level– Level of management engagement (Executive to executive)– Level of co-operative engagement i.e. sharing drug pipeline intentions– Deeper reliance on CRO scientific and therapeutic expertise
• Reduced internal capacity in the companies of strategic partners e.g. staff or asset transfers/reductions
• Clients likely to move their % outsourced from ≈ 30% to >50% over the next 5+ years
Market Fundamentals Still Intact
• Outsourcing Penetration expected to increase– More Strategic approach to outsourcing– Cost containment– Globalisation of clinical research
• Continued R&D Spending Growth.– Pipelines remain solid– Scientific innovation continues to expand
• Increasing Regulation – More patients/ more studies– Post marketing surveillance
Clinical Compounds in Development
R&D Spending Growth
CRO Market Size 1996 – 2012 (E)
Total Biotech Funding ($ Millions)
Market Fundamentals Still Intact
• Outsourcing Penetration expected to increase– More Strategic approach to outsourcing– Cost containment– Globalisation of clinical research
• Continued R&D Spending Growth.– Pipelines remain solid– Scientific innovation continues to expand
• Increasing Regulation – More patients/ more studies– Post marketing surveillance
Opportunities…. but also Risks
ICON in this Market Environment
1.6
1.2 1.2 1.2
0.8
Book to Bill Ratio Net Business Wins
Net New Business Wins and Book to Bill Ratio
Q3 09 Net Wins YTD 09 Net Wins
Analysis of Business Wins
Analysis of Backlog by client Q3 09
Total Backlog Level ($ Millions)
6%
Value of backlog forecast to be earned in next 4 quarters
Coverage of next 4 quarters from Backlog
Projects of Longer duration lead to slower backlog burn
Strategy
• Capitalise on market fundamentals to drive organic growth in all business units.
• Cross-sell services to grow sales and margin• Build Deep Strategic Relationships• Create Stronger differentiation across our services• Retain a flexible business model to respond to differing client
outsourcing strategies• Pursue acquisitions to enhance depth and scale of current operations
and to add additional complementary services e.g.
– Phase I – Bioanalytical / Biomarkers– Therapeutic specialists
– Safety/Late Phase– Imaging– Japan
Acquisitions to date – 13
• Revenues acquired $130m
• Staff acquired – 1,200
• => Organic growth >80%
ICON’s Core Strategy is Organic Growth,with acquisitions made to add new services or scale
Market Feedback
ICON in recent Surveys
“ICON is one of three CRO’s cited most frequently as sponsor’s favourite CRO vendors”
“Our confidence goes up that ICON is the right name to own in this environment, given their consistent quality”
““ ICON is a darling of the industry, the company's stunning growth in 2006 and 2007 surprised its peers. Now, the Dublin-based company is still outpacing just
about everybody, but at a less accelerated clip.”
Financial Performance
CAGR 28%
(E)
Net Revenue CAGR of 28% since 2005
* Mid point of Guidance Oct 21st
$0.43
$0.68
$0.94
$1.30
$1.50
$0.00
$0.20
$0.40
$0.60
$0.80
$1.00
$1.20
$1.40
FY2005 FY2006 FY2007 FY2008 FY2009*
CAGR 37%
Earnings Per Share Growth
* Mid point of Guidance October 21st
(E)
Cash Flow from Operations / Free Cash Flow
FCF Per Share
* Estimate assumes DSO of approx 60 days. Historic periods FCF exclude Head-office construction costs
Return on Equity
31 Sept 09 31 Sept 08 % Increase
Net Revenue 220 225 (2.3%)
Direct Costs 127 127 (0.6%)
SG & AEBITDA
5439
6435
(16.0%)10.7%
D & A 9 8 5.9%
EBIT 30 27 12.1%
Net Income 24 21 12.0%
EPS (Inc SFAS 123R) 40c 35c 14.3%
Weighted Average no. of Shares (Inc SFAS123R)
59.9m 61.8m (3.0%)
Recent Financial Performance($ millions) Quarter 3 2009
31 Sept 09 31 Sept 08 % Increase
Net Revenue 660 645 2.3%Direct Costs 376 364 (3.4%)SG & AEBITDA
174110
18794
(6.9%)17.5%
D & A 23 21 9.5%EBIT 87 73 18.6%Net Income 68 57 18.5%
EPS (Inc SFAS 123R) 113c 93c 21.5%Weighted Average no. of Shares (Inc SFAS123R)
59.7m 61.4m (2.6%)
Recent Financial Performance($ millions) YTD 2009
Summary Balance Sheet and Cash Flow($ millions)
9 Mths ended
Sept 31, 09
Full Year ended
Dec 31, 08
Full Year ended
Dec 31, 07
Full Year ended
Dec 31, 06Cash $173.0 $101.1 $118.6 $102.9
Debt $28.0 $105.4 $94.8 $5
Net Cash/Debt $145.0 ($4.3) $23.8 $97.9
Total assets $922.1 $867.3 $693.1 $476.3
Total Liabilities $381.3 $410.9 $304.9 $173.6
Shareholder’s equity $540.8 $456.4 $388.4 $302.7
Cashflow from operations
$198.4 $81.3 $42.9 $50.4
Capital expenditures $26.0 $67.9 $75.4 $31.5
YTDSept 31, 09
Full Year ended
Dec 31, 08
Full Year ended
Dec 31, 07
Full Year ended
Dec 31, 06
Sales Growth 2.3% 37% 38% 39%
EPS Growth 21.5% 38% 41% 177%
EBITDA Margin 16.7% 14.7% 14% 13.8%
EBIT Margin 13.1% 11.5% 11.0% 10.5%
ROE 18.0% 17% 14% 13%
ICON Key Financial Metrics($ millions)
ICON
S&P 500 Nasdaq Composite
ICON Plc Historic Share Price Performane
• Top Global Clinical CRO - #4• Deep customer relationships• Quality of staff• Experienced Management team• Excellent Reputation• Solid market fundamentals • Outstanding record of growth • Strong balance sheet
Investment Case Summary